Original Article
Drug-Eluting or Bare-Metal Stents for Acute Myocardial Infarction
N Engl J Med 2008; 359:1330-1342September 25, 2008
- Abstract
Background
Studies comparing percutaneous coronary intervention (PCI) with drug-eluting and bare-metal coronary stents in acute myocardial infarction have been limited in size and duration.
Methods
We identified all adults undergoing PCI with stenting for acute myocardial infarction between April 1, 2003, and September 30, 2004, at any acute care, nonfederal hospital in Massachusetts with the use of a state-mandated database of PCI procedures. We performed propensity-score matching on three groups of patients: all patients with acute myocardial infarction, all those with acute myocardial infarction with ST-segment elevation, and all those with acute myocardial infarction without ST-segment elevation. Propensity-score analyses were based on clinical, procedural, hospital, and insurance information collected at the time of the index procedure. Differences in the risk of death between patients receiving drug-eluting stents and those receiving bare-metal stents were determined from vital-statistics records.
Results
A total of 7217 patients were treated for acute myocardial infarction (4016 with drug-eluting stents and 3201 with bare-metal stents). According to analysis of matched pairs, the 2-year, risk-adjusted mortality rates were lower for drug-eluting stents than for bare-metal stents among all patients with myocardial infarction (10.7% vs. 12.8%, P=0.02), among patients with myocardial infarction with ST-segment elevation (8.5% vs. 11.6%, P=0.008), and among patients with myocardial infarction without ST-segment elevation (12.8% vs. 15.6%, P=0.04). The 2-year, risk-adjusted rates of recurrent myocardial infarction were reduced in patients with myocardial infarction without ST-segment elevation who were treated with drug-eluting stents, and repeat revascularization rates were significantly reduced with the use of drug-eluting stents as compared with bare-metal stents in all groups.
Conclusions
In patients presenting with acute myocardial infarction, treatment with drug-eluting stents is associated with decreased 2-year mortality rates and a reduction in the need for repeat revascularization procedures as compared with treatment with bare-metal stents.
Media in This Article
Figure 1
Clinical Outcomes after Stenting for Myocardial Infarction.Figure 2
Clinical Outcomes after Stenting for Myocardial Infarction with ST-Segment Elevation.Article Activity
- Article
Percutaneous coronary intervention (PCI) for acute myocardial infarction reduces the rates of death and recurrent ischemia as compared with medical therapy.1-3 In current clinical practice, both drug-eluting and bare-metal stents are commonly used. However, the randomized trials supporting the approval of drug-eluting stents excluded patients with acute myocardial infarction.4,5 Randomized studies comparing drug-eluting stents with bare-metal stents in patients with myocardial infarction have been relatively small (300 to 700 patients per study) and have had limited periods of follow-up (typically 1 year or less).6-11 In these trials, drug-eluting stents reduced the need for repeat revascularization procedures to treat restenosis as compared with bare-metal stents, but there were no significant differences between the two types of stents in the rates of death or subsequent myocardial infarction at 1 year.
Observational studies comparing drug-eluting and bare-metal stents in patients with acute myocardial infarction have had conflicting results.12,13 One study suggested that among patients surviving myocardial infarction with ST-segment elevation, the mortality rate between 6 months and 2 years in those treated with drug-eluting stents was more than twice that in those treated with bare-metal stents.14
We conducted a study on an unselected, population-based cohort of patients presenting with myocardial infarction who were treated with either drug-eluting or bare-metal stents. We sought to determine whether higher rates of death and recurrent myocardial infarction could be attributed to the use of drug-eluting stents rather than bare-metal stents among all patients, and specifically among those with and those without ST-segment elevation. Because the type of stent used was not randomly assigned, we used propensity-score matching to minimize bias.
Methods
Study Population
In 2002, the Massachusetts Department of Public Health established a requirement that all Massachusetts hospitals that provide interventional cardiology services collect data on all PCI procedures. These data are prospectively collected by trained hospital personnel with the use of the National Cardiovascular Data Registry data-collection instrument (www.accncdr.com/WebNCDR/Common) of the American College of Cardiology. The data are then submitted electronically to the Massachusetts Data Analysis Center at Harvard Medical School, where they are audited, adjudicated by a committee of interventionalists, and verified with the use of internal and external procedures.15 The Massachusetts Data Analysis Center also maintains a similar state-mandated cardiac-surgery database.
We performed our analysis with the use of the Massachusetts Data Analysis Center database. The study was designed and conducted by the authors and funded by the Massachusetts Department of Public Health. Dr. Normand vouches for the integrity, accuracy, and completeness of the data and the analyses. The study was approved by the Committee on Human Studies at Harvard Medical School.
Analysis Cohort
We identified all adults (18 years of age or older) undergoing PCI with stenting for acute myocardial infarction between April 1, 2003, and September 30, 2004, at all acute care, nonfederal hospitals in Massachusetts. To preclude incomplete ascertainment of subsequent adverse events, subjects were excluded from this analysis if they were not Massachusetts residents at the time of the procedure or if they could not be linked to hospital-discharge billing records.
Study subjects were assigned to either the drug-eluting-stent group or the bare-metal-stent group according to the stent type used during the index admission. Patients receiving both drug-eluting and bare-metal stents during the index admission were excluded from the analysis.
Study Outcomes
The primary outcome was death from any cause within 2 years after the index procedure. In-hospital mortality information at the time of the index procedure was reported directly to the Massachusetts Data Analysis Center by the hospitals. This information was verified with the use of data from the Massachusetts Registry of Vital Records and Statistics, which also provided 2-year mortality data for all study participants at the time of analysis. The Social Security Death Index Interactive Search Web site (http://ssdi.rootsweb.com/cgi-bin/ssdi.cgi) was used to confirm mortality status as recorded by the Registry of Vital Records and Statistics and to resolve cases in which the Massachusetts vital statistics data disagreed with the Massachusetts Data Analysis Center data.
Secondary outcomes included recurrent myocardial infarction and repeat revascularization. Recurrent myocardial infarction occurring during the index hospitalization was determined from the mandatory recording of in-hospital events in the Massachusetts Data Analysis Center database according to the National Cardiovascular Data Registry definitions. Myocardial infarctions occurring during any subsequent hospital admission were identified by linking the Massachusetts Data Analysis Center data to hospital-discharge billing data collected by the Massachusetts Division of Health Care Finance and Policy. Repeat target-vessel revascularization was defined as PCI performed in a vessel treated during the index procedure or any coronary-artery bypass grafting (CABG) procedure performed after the index procedure. Information regarding CABG and PCI was obtained from the Massachusetts Data Analysis Center databases.
Confounding Variables
We developed a list of potential confounders, including demographic factors, insurance status, medical history, and risk factors of the patient; characteristics of the lesion and the procedure; and medications received by the patients. Because some patients were treated for multiple lesions during their index admission, we created patient-specific, lesion-based variables, including maximum stenosis as a percentage of arterial diameter, any high-risk lesion, and any use of thrombectomy. Because some hospitals in Massachusetts have pilot programs that perform only primary PCI without performing surgery on site, we also included a variable that indicated whether the patient underwent the PCI in a pilot program. Data on the majority of the confounders were obtained from the Massachusetts Data Analysis Center database, and data on two confounders were obtained from hospital-discharge billing data for the index admission.
Statistical Analysis
Because the patients were not randomly assigned to receive drug-eluting stents, we used propensity-score matching to adjust for differences in baseline characteristics.16 We performed a one-to-one matched analysis without replacement on the basis of the estimated propensity score of each patient. The log odds of the probability that a patient received a drug-eluting stent (the “logit”) was modeled as a function of the confounders that we identified and included in our data set. Using the estimated logits, we first randomly selected a patient in the group receiving drug-eluting stents and then matched that patient with the patient in the group receiving bare-metal stents with the closest estimated logit value. Patients in the group receiving bare-metal stents who had an estimated logit within 0.6 SD of the selected patients in the group receiving drug-eluting stents were eligible for matching. We selected 0.6 because this value has been shown to eliminate approximately 90% of the bias in observed confounders.17 If more than one patient in the group receiving bare-metal stents met this criterion, we randomly selected one patient for matching.
We analyzed the data according to three different propensity-score models: one for any myocardial infarction, one for myocardial infarction with ST-segment elevation, and one for myocardial infarction without ST-segment elevation. To assess the success of the matching procedure, we measured standardized differences (measured in percentage points) in observed confounders between the matched groups after matching.
Using the matched pairs, we performed paired t-tests to determine whether rates of death, myocardial infarction, and repeat revascularization differed between recipients of drug-eluting stents and recipients of bare-metal stents. Estimates of the adjusted differences in risks are presented, with 95% confidence intervals. All P values presented are two-sided.
Because matching on the propensity score cannot be expected to balance for unobserved confounders that are independent of observed confounders, we performed several sensitivity analyses. First, we examined differences between the two stent groups in mortality rates 2 days after stent placement. A large difference would indicate residual confounding, because such an early benefit would be unlikely.
Second, the initiation of this study coincided with the introduction of drug-eluting stents in Massachusetts in late April 2003. We observed that the use of drug-eluting stents increased during our observation period (Fig. 1 in the Supplementary Appendix, available with the full text of this article at www.nejm.org) and that the time course of adoption varied according to whether the hospital performed PCI under a pilot program or a nonpilot program. In order to evaluate whether these temporal trends influenced the study results, we reestimated propensity scores that, in addition to our initial set of confounders, included time (measured as days since April 1, 2003), a quadratic term for time, and an interaction between time and type of hospital program (pilot or nonpilot). We then used these propensity scores to obtain a restricted matched cohort and compare risks after treatment with a drug-eluting stent and after treatment with a bare-metal stent.
Finally, we performed propensity-matched analyses of two subgroups of patients from the cohort of patients who had a myocardial infarction with ST-segment elevation. One of these subgroups excluded patients treated in hospitals with pilot programs, and the other excluded patients treated more than 24 hours after the onset of symptoms.
Results
Between April 1, 2003, and September 30, 2004, there were 21,045 adult patients who underwent PCI with stenting in Massachusetts. Of these, 8440 patients (40%) presented with acute myocardial infarction (Fig. 2 in the Supplementary Appendix). We excluded 576 patients who were not residents of Massachusetts, 167 patients who were not linkable to hospital-discharge data, and 480 patients who were treated with both drug-eluting and bare-metal stents. The resulting cohort of 7217 patients underwent stenting by 119 operators at 21 hospitals. Of these patients, 4016 were treated with drug-eluting stents and 3201 were treated with bare-metal stents. Of the patients treated with drug-eluting stents, 71% received sirolimus-eluting stents only, 27% received paclitaxel-eluting stents only, and 2% received both types of drug-eluting stents. Of the 7217 patients included, 3379 underwent stenting for myocardial infarction with ST-segment elevation and 3838 underwent stenting for myocardial infarction without ST-segment elevation.
Before propensity-score matching, patients treated with drug-eluting stents and those treated with bare-metal stents differed significantly in clinical and procedural characteristics (Table 1Table 1
Characteristics of Patients before Propensity-Score Matching. and Table 2Table 2
Characteristics of Procedures before Propensity-Score Matching.). Patients with diabetes mellitus, hyperlipidemia, hypertension, or myocardial infarction without ST-segment elevation were more likely to be treated with drug-eluting stents than with bare-metal stents. Also, the numbers of vessels and lesions treated were higher in patients treated with drug-eluting stents than in those treated with bare-metal stents. In contrast, patients with cardiogenic shock or myocardial infarction with ST-segment elevation, those undergoing emergency procedures, and those with high-risk lesions were more likely to be treated with bare-metal stents.The unadjusted rates of death, myocardial infarction, and repeat revascularization at 2 years were significantly lower among patients receiving drug-eluting stents than among those receiving bare-metal stents (Table 1 in the Supplementary Appendix). Patients treated for myocardial infarction with ST-segment elevation had lower rates of death and myocardial infarction at 2 years than those treated for myocardial infarction without ST-segment elevation, but there was no difference between these two groups in the rate of repeat revascularization.
The propensity-score models included up to 63 variables, depending on the subgroup. The matching of patients presenting with any acute myocardial infarction yielded 2570 patients treated with drug-eluting stents matched with 2570 patients treated with bare-metal stents. The area under the receiver-operating-characteristic curve (AUC) for this model was 0.68. Standardized differences were less than 10% for all matched variables (Tables 2 through 7 in the Supplementary Appendix), a result that supports the assumption of balance between treatment groups18 in observed confounders. Separate propensity-score matches were performed for patients who had myocardial infarction with ST-segment elevation (1298 matched pairs; AUC, 0.67) and for patients who had myocardial infarction without ST-segment elevation (1228 matched pairs; AUC, 0.66).
After propensity-score matching, we examined each of the study end points (Table 3Table 3
Two-Year Adjusted Clinical Outcomes. and Figure 1Figure 1Clinical Outcomes after Stenting for Myocardial Infarction., Figure 2Figure 2Clinical Outcomes after Stenting for Myocardial Infarction with ST-Segment Elevation., and Figure 3Figure 3
Clinical Outcomes after Stenting for Myocardial Infarction without ST-Segment Elevation.). With respect to the primary outcome, drug-eluting stents were associated with significantly lower mortality at 2 years than were bare-metal stents in the matched cohort of patients with any myocardial infarction (10.7% vs. 12.8%; risk difference, –2.1%; 95% confidence interval [CI], –3.8% to –0.4%; P=0.02). This difference was also significant in the matched cohort of patients who had myocardial infarction with ST-segment elevation (8.5% vs. 11.6%; risk difference, –3.1%; 95% CI, –5.4% to –0.8%; P=0.008) and in the matched cohort of patients who had myocardial infarction without ST-segment elevation (12.8% vs. 15.6%; risk difference, –2.9%; 95% CI, –5.5% to –0.2%; P=0.04).After propensity-score matching, there was no significant difference in the rate of reinfarction at 2 years between patients receiving drug-eluting stents and those receiving bare-metal stents (8.8% vs. 10.2%; risk difference, –1.4%; 95% CI, –3.0% to 0.2%; P=0.09), except for patients who had myocardial infarction without ST-segment elevation (10.3% vs. 13.3%; risk difference, –3.0%; 95% CI, –5.6% to –0.5%; P=0.02). The rates of repeat target-vessel revascularization at 2 years in the matched cohort of patients with any myocardial infarction were significantly lower among patients receiving drug-eluting stents than among those receiving bare-metal stents (9.6% vs. 14.5%; risk difference, –4.9%; 95% CI, –6.7% to –3.1%; P<0.001). A similar reduction in repeat target-vessel revascularization was evident for both subtypes of myocardial infarction.
Among all patients with myocardial infarction who received stents, the risk-adjusted mortality 2 days after stent placement was 0.7% in the group receiving drug-eluting stents and 1.2% in the group receiving bare-metal stents (risk difference, –0.5%; 95% CI, –1.0% to 0.0%; P=0.06). The corresponding risk differences were statistically significant for patients who had myocardial infarction with ST-segment elevation (risk difference, –0.9%; P=0.04) but not for patients who had myocardial infarction without ST-segment elevation (risk difference, –0.3%; P=0.32) (Table 8 in the Supplementary Appendix). Adjustment for the length of time after the introduction of drug-eluting stents tended to confirm the results of the primary analysis: event rates in the group receiving drug-eluting stents were either similar to or lower than those in the group receiving bare-metal stents (Fig. 1 and Table 9 in the Supplementary Appendix). After the exclusion of patients who were treated at hospitals without cardiac surgery on site or of patients who presented more than 24 hours after the onset of symptoms, the risk differences for death after myocardial infarction with ST-segment elevation were consistent with the primary findings (Table 10 in the Supplementary Appendix).
Discussion
Coronary-artery stenting is commonly performed to treat myocardial infarction. Acute coronary syndromes and myocardial infarction (in contrast to stable angina)19 are the only clinical presentations in which PCI has been shown to reduce the rate of death to a rate lower than that achieved with medical therapy alone.1-3 Despite the important role of stenting in patients with myocardial infarction and, in particular, in those who have myocardial infarction with ST-segment elevation, there has been little information regarding the long-term efficacy or safety of drug-eluting stents among these patients.
During the interval evaluated in our study, patients presenting with myocardial infarction accounted for 40% of stent procedures. These patients were split almost evenly between those with and those without ST-segment elevation. The rates of use of drug-eluting and bare-metal stents were nearly equal among all the patients that we studied, but because stent assignment was not random, we used propensity-score matching to adjust for imbalances in the measured characteristics of the patients, procedures, and hospitals in order to compare outcomes associated with the choice of stent.
Although our primary goal was to evaluate whether drug-eluting stents were associated with increased rates of myocardial infarction and death at long-term follow-up, we observed small absolute differences in mortality that favored drug-eluting stents in matched patient cohorts. These observations were consistent for all myocardial infarctions and for both subtypes of myocardial infarction.
Previous studies have reported an association between restenosis and the risk of death or myocardial infarction.20,21 A matched, population-based analysis of patients receiving drug-eluting stents or bare-metal stents (not restricted to patients with myocardial infarction) reported a similar reduction in 2-year mortality rates.22 Within the first year of follow-up, drug-eluting stents reduced the need for procedures to treat restenosis. Performing fewer procedures may have resulted in small reductions in the rates of death and myocardial infarction.
Some of the observed benefit, however, was apparent within the first 6 months, before the maximum effect of restenosis prevention would be apparent. This result suggests that additional factors, such as the duration of dual antiplatelet therapy, which is known to provide benefit in acute coronary syndromes, might have had a role.23,24 We adjusted for use of and contraindications to dual antiplatelet therapy. However, we were unable to adjust for the duration of therapy, which during the study period was probably 1 month for bare-metal stents and 3 to 6 months for drug-eluting stents, according to the manufacturers' instructions for use, rather than the 12 months recommended in the United States since 2007.25 We were also unable to assess and adjust for adherence to this therapy.
We found that among all patients with myocardial infarction, the absolute difference between those receiving drug-eluting stents and those receiving bare-metal stents in the rate of repeat revascularization of the treated vessel was approximately 5%, which was similar in magnitude to the absolute difference observed in populations of patients treated with stents for any indication.26,27 In fact, because the absolute rates of repeat revascularization are lower in patients who have had a myocardial infarction than in patients who have not had a myocardial infarction, the relative difference in the rate of repeat revascularization between patients receiving drug-eluting stents and those receiving bare-metal stents was actually larger among patients who had had a myocardial infarction than we have observed among all stent recipients.26
Our findings should be interpreted in the context of our study design and its limitations. First, it has been postulated that the difference in the biologic response to drug-eluting stents as compared with bare-metal stents may be greater in the presence of a thrombotic occlusion28 and may lead to a higher risk of stent thrombosis or adverse clinical events with the placement of drug-eluting stents in patients with a thrombotic occlusion.29 Although no difference in the rates of clinical sequelae of stent thrombosis was present, the rates of stent thrombosis could not be directly ascertained from our data.
Second, our data are observational. We used propensity-score matching to make the patient groups comparable according to the measured confounders, and we successfully eliminated the observed differences. However, residual confounding cannot be excluded. Our analysis of 2-day adjusted mortality rates in patients with ST-segment elevation showed a small but statistically significant difference in event rates between the two stent groups. Such a difference is unlikely to be related to the choice of stent and suggests that some residual confounding is present.
Possible sources of residual bias are differences in use of concomitant medical therapy or completeness of revascularization, if such differences are associated with the choice of stent. In addition, although we adjusted for the presence of cardiogenic shock, we did not have data on infarct size, an important predictor of death in patients with myocardial infarction. Finally, we did not have access to quantitative angiographic findings. This is a potential limitation, because drug-eluting stents were not available in the same range of vessel diameters as bare-metal stents. In particular, small-vessel stenting is known to be associated with higher risks both during the procedure and during follow-up.
Finally, the primary purpose of our analysis was to determine whether there was any harm associated with the use of drug-eluting stents as compared with bare-metal stents in an unselected population of patients with myocardial infarction. The observation of a reduction in mortality rates with drug-eluting stents was unanticipated and merits confirmation in randomized trials.30
In conclusion, in patients with myocardial infarction treated with stenting, the use of drug-eluting stents is associated with reduced rates of death and repeat revascularization at 2 years of follow-up, as compared with the use of bare-metal stents. Large, randomized trials with long-term follow-up will be necessary to confirm this observation.
Supported by a Massachusetts Department of Public Health contract (620022A4PRE) with Dr. Normand, Ms. Lovett, Ms. Silbaugh, Ms. Zelevinsky, and Mr. Wolf.
Dr. Mauri reports receiving lecture fees from Medtronic Vascular, Abbott Vascular, Boston Scientific, and Cordis. No other potential conflict of interest relevant to this article was reported.
We thank Paul Dreyer, Ph.D., of the Massachusetts Department of Public Health and Kurt Barringhaus, M.D., Clifford J. Berger, M.D., David Cohen, M.D., Angela Corey, Jean Crossman, R.N., Daniel Fisher, M.D., Joseph Garasic, M.D., Jean-Pierre Geagea, M.D., Gregory Giugliano, M.D., Kalon Ho, M.D., Alice Jacobs, M.D., James Kirshenbaum, M.D., Josh Krasnow, M.D., Anthony Marks, M.D., Theo E. Meyer, M.D., Ph.D., Kathy Minahan, R.N., Zoran Nedelijkovic, M.D., Barbara Oxley, R.N., Thomas C. Piemonte, M.D., Kenneth Rosenfield, M.D., Pinak B. Shah, M.D., Samuel J. Shubrooks, Jr., M.D., James Waters, M.D., and Bonnie Weiner, M.D., of the Massachusetts Data Analysis Center PCI Data Adjudication Committee for their assistance; and the Division of Health Care Finance and Policy of the Commonwealth of Massachusetts for providing the billing data.
Source Information
From Brigham and Women's Hospital (L.M., P.G., M.R.V., Z.Z.), the Harvard Clinical Research Institute (L.M.), Harvard Medical School (L.M., T.S.S., R.E.W., K.Z., A.L., S.-L.T.N.), and the Harvard School of Public Health (S.-L.T.N.) — all in Boston.
Address reprint requests to Dr. Mauri at Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, or at lmauri1@partners.org.
- References
References
1
Bavry AA ,Kumbhani DJ ,Quiroz R ,Ramchandani SR ,Kenchaiah S ,Antman EM . Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improves survival in non-ST-segment elevation acute coronary syndromes: a meta-analysis and review of the literature. Am J Cardiol 2004;93:830-835
CrossRef | Web of Science | Medline2
Keeley EC ,Boura JA ,Grines CL . Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13-20
CrossRef | Web of Science | Medline3
Mehta SR ,Cannon CP ,Fox KA , et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 2005;293:2908-2917
CrossRef | Web of Science | Medline4
Moses JW ,Leon MB ,Popma JJ , et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323
Full Text | Web of Science | Medline5
Stone GW ,Ellis SG ,Cox DA , et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231
Full Text | Web of Science | Medline6
Laarman GJ ,Suttorp MJ ,Dirksen MT , et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006;355:1105-1113
Full Text | Web of Science | Medline7
Menichelli M ,Parma A ,Pucci E , et al. Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). J Am Coll Cardiol 2007;49:1924-1930
CrossRef | Web of Science | Medline8
Spaulding C ,Henry P ,Teiger E , et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006;355:1093-1104
Full Text | Web of Science | Medline9
van der Hoeven BL ,Liem SS ,Jukema JW , et al. Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. J Am Coll Cardiol 2008;51:618-626
CrossRef | Web of Science | Medline10
Kastrati A ,Dibra A ,Spaulding C , et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 2007;28:2706-2713
CrossRef | Web of Science | Medline11
Valgimigli M ,Percoco G ,Malagutti P , et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005;293:2109-2117
CrossRef | Web of Science | Medline12
Lemos PA ,Saia F ,Hofma SH , et al. Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol 2004;43:704-708
CrossRef | Web of Science | Medline13
Slottow TL ,Steinberg DH ,Roy P , et al. Drug-eluting stents are associated with similar cardiovascular outcomes when compared to bare metal stents in the setting of acute myocardial infarction. Cardiovasc Revasc Med 2008;9:24-28
CrossRef | Medline14
Steg PG. Increased all-cause mortality at 2-year follow-up after PCI with drug-eluting stents versus bare-metal stents in acute coronary syndromes: the GRACE Registry. Presented at the European Society of Cardiology World Congress, Vienna, September 1–5, 2007.
15
Shahian DM ,Silverstein T ,Lovett AF ,Wolf RE ,Normand SL . Comparison of clinical and administrative data sources for hospital coronary artery bypass graft surgery report cards. Circulation 2007;115:1518-1527
CrossRef | Web of Science | Medline16
D'Agostino RB Jr . Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-2281
CrossRef | Web of Science | Medline17
Gu XS ,Rosenbaum PR . Comparison of multivariate matching methods: structures, distances, and algorithms. J Comput Graph Stat 1993;2:405-420
CrossRef18
Cohen J. The t test for means. In: Cohen J, ed. Statistical power analysis for the behavioral sciences. Toronto: Academic Press, 1977:19-74.
19
Boden WE ,O'Rourke RA ,Teo KK , et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503-1516
Full Text | Web of Science | Medline20
Chen MS ,John JM ,Chew DP ,Lee DS ,Ellis SG ,Bhatt DL . Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006;151:1260-1264
CrossRef | Web of Science | Medline21
Doyle B ,Rihal CS ,O'Sullivan CJ , et al. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation 2007;116:2391-2398
CrossRef | Web of Science | Medline22
Tu JV ,Bowen J ,Chiu M , et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 2007;357:1393-1402
Full Text | Web of Science | Medline23
Mehta SR ,Yusuf S ,Peters RJ , et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-533
CrossRef | Web of Science | Medline24
Sabatine MS ,Cannon CP ,Gibson CM , et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-1189
Full Text | Web of Science | Medline25
Grines CL ,Bonow RO ,Casey DE Jr , et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007;115:813-818
CrossRef | Web of Science | Medline26
Mauri L, Silbaugh TS, Wolf RE, et al. Long-term clinical outcomes following drug-eluting and bare metal stenting in Massachusetts. Circulation (in press).
27
Abbott JD ,Voss MR ,Nakamura M , et al. Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: findings from the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol 2007;50:2029-2036
CrossRef | Web of Science | Medline28
Cook S ,Wenaweser P ,Togni M , et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007;115:2426-2434
CrossRef | Web of Science | Medline29
Sianos G ,Papafaklis MI ,Daemen J , et al. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol 2007;50:573-583
CrossRef | Web of Science | Medline30
Stone GW. HORIZONS-AMI: a prospective randomized comparison of bivalirudin vs. heparin plus glycoprotein IIb/IIIa inhibitors during primary angioplasty in acute myocardial infarction. Presented at the 19th annual Transcatheter Cardiovascular Therapeutic symposium, Washington, DC, October 20–25, 2007.
- Citing Articles (75)
Citing Articles
1
Yun-Jau Chang, Li-Ju Chen, Yao-Jen Chang, Kuo-Piao Chung, Mei-Shu Lai. (2012) Application of propensity score model to examine the prognostic significance of lymph node number as a care quality indicator. Surgical Oncology
CrossRef2
Ki-Woon Kang, Young-Guk Ko, Dong-Ho Shin, Jung-Sun Kim, Byeong-Keuk Kim, Donghoon Choi, Yangsoo Jang, Myeong-Ki Hong. (2012) Comparison of Vascular Remodeling in Patients Treated With Sirolimus-Versus Zotarolimus-Eluting Stent Following Acute Myocardial Infarction. Clinical Cardiology 35:1, 49-54
CrossRef3
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Journal of the American College of Cardiology 58:24, e44-e122
CrossRef4
, B. Scheller, B. Levenson, M. Joner, R. Zahn, V. Klauss, C. Naber, V. Schächinger, A. Elsässer. (2011) Medikamente freisetzende Koronarstents und mit Medikamenten beschichtete Ballonkatheter. Der Kardiologe 5:6, 411-435
CrossRef5
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. Journal of the American College of Cardiology 58:24, 2550-2583
CrossRef6
Michael Mahmoudi, Cedric Delhaye, Ron Waksman. (2011) Safety and efficacy of drug-eluting stents and bare metal stents in acute coronary syndrome. Cardiovascular Revascularization Medicine 12:6, 385-390
CrossRef7
Masami Nishino, Takahiro Yoshimura, Daisuke Nakamura, Yasuharu Lee, Masayuki Taniike, Nobuhiko Makino, Hiroyasu Kato, Yasuyuki Egami, Ryu Shutta, Jun Tanouchi, Yoshio Yamada. (2011) Comparison of Angioscopic Findings and Three-Year Cardiac Events Between Sirolimus-Eluting Stent and Bare-Metal Stent in Acute Myocardial Infarction. The American Journal of Cardiology 108:9, 1238-1243
CrossRef8
David Planer, Pieter C. Smits, Dean J. Kereiakes, Elvin Kedhi, Martin Fahy, Ke Xu, Patrick W. Serruys, Gregg W. Stone. (2011) Comparison of Everolimus- and Paclitaxel-Eluting Stents in Patients With Acute and Stable Coronary Syndromes. JACC: Cardiovascular Interventions 4:10, 1104-1115
CrossRef9
KISHORE J. HARJAI, SUDHAKAR SATTUR, PAMELA ORSHAW, JUDY BOURA. (2011) Long-Term Safety and Effectiveness of Drug-Eluting Stents Compared to Bare Metal Stents following Successful PCI in Non-ST-Elevation Myocardial Infarction: Findings from the Guthrie Health Off-Label StenT (GHOST) Registry. Journal of Interventional Cardiologyno-no
CrossRef10
PEDRO BERALDO DE ANDRADE, MARDEN ANDRÉ TEBET, FELIPE SOUZA MAIA DA SILVA, MÔNICA VIEIRA ATHANAZIO DE ANDRADE, ANDRÉ LABRUNIE, LUIZ ALBERTO PIVA E MATTOS. (2011) Drug-Eluting Stents during ST-Segment Elevation Acute Myocardial Infarction: A Critical Analysis. Journal of Interventional Cardiology 24:5, 416-423
CrossRef11
Nobuo Sakamoto, Kazuhiko Nakazato, Tomofumi Misaka, Hiroyuki Mizukami, Hiroyuki Kunii, Hitoshi Suzuki, Shu-ichi Saitoh, Yasuchika Takeishi. (2011) Very late stent thrombosis and neointimal plaque rupture after implantation of sirolimus-eluting stents: observations with angiography, IVUS and OCT. Cardiovascular Intervention and Therapeutics 26:3, 263-268
CrossRef12
Raffaele Piccolo, Salvatore Cassese, Gennaro Galasso, Roberta De Rosa, Carolina D’Anna, Federico Piscione. (2011) Long-term safety and efficacy of drug-eluting stents in patients with acute myocardial infarction: A meta-analysis of randomized trials. Atherosclerosis 217:1, 149-157
CrossRef13
Philippe Commeau. (2011) Prise en charge de l’infarctus du myocarde : comment améliorer l’angioplastie primaire ?. La Presse Médicale 40:6, 606-610
CrossRef14
Edward L. Hannan, Zaza Samadashvili, Gary Walford, David R. Holmes, Alice K. Jacobs, Nicholas J. Stamato, Ferdinand J. Venditti, Samin Sharma, Icilma Fergus, Spencer B. King. (2011) Comparison of Outcomes for Patients Receiving Drug-Eluting Versus Bare Metal Stents for Non–ST-Segment Elevation Myocardial Infarction. The American Journal of Cardiology 107:9, 1311-1318
CrossRef15
K-H. Yu, K-S. Hong, B-C. Lee, M-S. Oh, Y-J. Cho, J-S. Koo, J-M. Park, H-J. Bae, M-K. Han, Y-S. Ju, D-W. Kang, P. Appelros, B. Norrving, A. Terent. (2011) Comparison of 90-day case-fatality after ischemic stroke between two different stroke outcome registries using propensity score matching analysis. Acta Neurologica Scandinavica 123:5, 325-331
CrossRef16
Ajay J. Kirtane, Adriano Caixeta, Philippe Généreux, Rikesh Patel, Jeffrey W. Moses. 2011. Sirolimus and Paclitaxel Eluting Stent Clinical Studies. , 502-518.
CrossRef17
Ioannis Tentzeris, Rudolf Jarai, Serdar Farhan, Johann Wojta, Martin Schillinger, Alexander Geppert, Michael Nürnberg, Gerhard Unger, Kurt Huber. (2011) Long-term outcome after drug-eluting stent implantation in comparison with bare metal stents: a single centre experience. Clinical Research in Cardiology 100:3, 191-200
CrossRef18
Walid Maamoun, Nabil Elkhaeat, Rasha Elarasy. (2011) Safety and feasibility of complete simultaneous revascularization during primary PCI in patients with STEMI and multi-vessel disease. The Egyptian Heart Journal 63:1, 39-43
CrossRef19
Alamgir MN Kabir, Amalan Selvarajah, Alexander M Seifalian. (2011) How safe and how good are drug-eluting stents?. Future Cardiology 7:2, 251-270
CrossRef20
Pow-Li Chia, Arul Earnest, Jimmy Lim. (2011) Biolimus-eluting biodegradable polymer-coated stent versus bare metal stent in acute ST-elevation and non-ST elevation myocardial infarction: Justification for biodegradable polymer-coated stent in acute coronary syndrome (JANICE) registry. Acute Cardiac Care 13:1, 43-47
CrossRef21
David M. Charytan, Manu R. Varma, Treacy S. Silbaugh, Ann F. Lovett, Sharon-Lise T. Normand, Laura Mauri. (2011) Long-term Clinical Outcomes Following Drug-Eluting or Bare-Metal Stent Placement in Patients With Severely Reduced GFR: Results of the Massachusetts Data Analysis Center (Mass-DAC) State Registry. American Journal of Kidney Diseases 57:2, 202-211
CrossRef22
Doo Sun Sim, Myung Ho Jeong, Youngkeun Ahn, Young Jo Kim, Shung Chull Chae, Taek Jong Hong, In Whan Seong, Jei Keon Chae, Chong Jin Kim, Myeong Chan Cho, Ki Bae Seung, Seung Jung Park, . (2011) Effectiveness of Drug-Eluting Stents versus Bare-Metal Stents in Large Coronary Arteries in Patients with Acute Myocardial Infarction. Journal of Korean Medical Science 26:4, 521
CrossRef23
Robert W Yeh, Malini Chandra, Charles E McCulloch, Alan S Go. (2011) Accounting for the mortality benefit of drug-eluting stents in percutaneous coronary intervention: a comparison of methods in a retrospective cohort study. BMC Medicine 9:1, 78
CrossRef24
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting, Alice K. Jacobs, Jeffrey L. Anderson, Nancy Albert, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Frederick G. Kushner, E. Magnus Ohman, William Stevenson, Clyde W. Yancy. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef25
Koyu Sakai, Shinya Nagayama, Kasumi Ihara, Kenji Ando, Shinichi Shirai, Katsuhiro Kondo, Hiroyoshi Yokoi, Masashi Iwabuchi, Hideyuki Nosaka, Masakiyo Nobuyoshi. (2011) Primary percutaneous coronary intervention for acute myocardial infarction in the elderly aged ≥75 years. Catheterization and Cardiovascular Interventions 79:1, 50-56
CrossRef26
Yanai Ben-Gal, Jeffrey W. Moses, Roxana Mehran, Alexandra J. Lansky, Giora Weisz, Eugenia Nikolsky, Michael Argenziano, Matthew R. Williams, Antonio Colombo, Philip E. Aylward, Gregg W. Stone. (2010) Surgical Versus Percutaneous Revascularization for Multivessel Disease in Patients With Acute Coronary Syndromes. JACC: Cardiovascular Interventions 3:10, 1059-1067
CrossRef27
David R. Holmes, Dean J. Kereiakes, Scot Garg, Patrick W. Serruys, Gregory J. Dehmer, Stephen G. Ellis, David O. Williams, Takeshi Kimura, David J. Moliterno. (2010) Stent Thrombosis. Journal of the American College of Cardiology 56:17, 1357-1365
CrossRef28
Xiao-hong Pan, Ying-xue Chen, Mei-xiang Xiang, Geng Xu, Jian-an Wang. (2010) A meta-analysis of randomized trials on clinical outcomes of paclitaxel-eluting stents versus bare-metal stents in ST-segment elevation myocardial infarction patients. Journal of Zhejiang University SCIENCE B 11:10, 754-761
CrossRef29
Warren Kyle Stribling, Antonio Abbate, Michael Kontos, George W Vetrovec, Kapildeo Lotun. (2010) Myocardial infarctions involving acute left circumflex occlusion: are all occlusions created equally?. Interventional Cardiology 2:5, 695-704
CrossRef30
Manivannan Srinivasan, Charanjit S. Rihal, Mandeep Singh, Ryan J. Lennon, David R. Holmes, Abhiram Prasad. (2010) Percutaneous Coronary Intervention in Native Vessels With Angiographically Visible Thrombus. JACC: Cardiovascular Interventions 3:9, 937-946
CrossRef31
Srinivas Iyengar, LeRoy E Rabbani. (2010) Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction: Drug-Eluting Stents or Bare Metal Stents?. American Journal of Therapeutics 17:5, 516-522
CrossRef32
Tamir Bental, Abid Assali, Hana Vaknin-Assa, Eli I. Lev, David Brosh, Shmuel Fuchs, Alexander Battler, Ran Kornowski. (2010) A comparative analysis of major clinical outcomes using drug-eluting stents versus bare-metal stents in a large consecutive patient cohort. Catheterization and Cardiovascular Interventions 76:3, 374-380
CrossRef33
Masami Nishino, Shiro Hoshida, Masayuki Taniike, Hiroyasu Kato, Yasuyuki Egami, Ryu Shutta, Hitoshi Yamaguchi, Kenjiro Tanaka, Jun Tanouchi, Yoshio Yamada. (2010) Vulnerable disease may induce neointimal coverage after silorimus-eluting stent implantation. American Heart Journal 160:3, 564-569
CrossRef34
Klaus A. Tiroch, Dirk Sibbing, Werner Koch, Tobias Roosen-Runge, Julinda Mehilli, Albert Schömig, Adnan Kastrati. (2010) Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. American Heart Journal 160:3, 506-512
CrossRef35
Jael Z. Atary, Bas L. van der Hoeven, Su San Liem, J. Wouter Jukema, Johanna G. van der Bom, Douwe E. Atsma, Marianne Bootsma, Katja Zeppenfeld, Ernst E. van der Wall, Martin J. Schalij. (2010) Three-Year Outcome of Sirolimus-Eluting Versus Bare-Metal Stents for the Treatment of ST-Segment Elevation Myocardial Infarction (from the MISSION! Intervention Study). The American Journal of Cardiology 106:1, 4-12
CrossRef36
A. Abelson, J. D. Ringe, D. T. Gold, J. L. Lange, T. Thomas. (2010) Longitudinal change in clinical fracture incidence after initiation of bisphosphonates. Osteoporosis International 21:6, 1021-1029
CrossRef37
Alban Dibra, Klaus Tiroch, Stefanie Schulz, Henning Kelbæk, Christian Spaulding, Gerrit J. Laarman, Marco Valgimigli, Emilio Lorenzo, Christoph Kaiser, Ilkka Tierala, Julinda Mehilli, Gianluca Campo, Leif Thuesen, Maarten A. Vink, Martin J. Schalij, Roberto Violini, Albert Schömig, Adnan Kastrati. (2010) Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials. Clinical Research in Cardiology 99:6, 345-357
CrossRef38
Youngjin Cho, Han-Mo Yang, Kyung-Woo Park, Woo-Young Chung, Dong-Joo Choi, Won-Woo Seo, Kyoung-Tae Jeong, Sung-Chul Chae, Myoung-Yong Lee, Seung-Ho Hur, Jei-Keon Chae, In-Whan Seong, Jung-Han Yoon, Suk-Kyu Oh, Doo-Il Kim, Keum-Soo Park, Seung-Woon Rha, Yang-Soo Jang, Jang-Ho Bae, Taeg-Jong Hong, Myeong-Chan Cho, Young-Jo Kim, Myung-Ho Jeong, Min-Jung Kim, Sue K. Park, In-Ho Chae, Hyo-Soo Kim. (2010) Paclitaxel- Versus Sirolimus-Eluting Stents for Treatment of ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions 3:5, 498-506
CrossRef39
Gianluca Campo, Francesco Saia, Gianfranco Percoco, Antonio Manari, Andrea Santarelli, Luigi Vignali, Elisabetta Varani, Alberto Benassi, Pietro Sangiorgio, Fabio Tarantino, Paolo Magnavacchi, Rossana De Palma, Paolo Guastaroba, Antonio Marzocchi. (2010) Long-term outcome after drug eluting stenting in patients with ST-segment Elevation Myocardial Infarction. International Journal of Cardiology 140:2, 154-160
CrossRef40
George W. Vetrovec. (2010) Evidence-based management of patients undergoing PCI: Stent controversies. Catheterization and Cardiovascular Interventions 75:S1, S39-S42
CrossRef41
Asmir I. Syed, Itsik Ben-Dor, Yanlin Li, Sara D. Collins, Manuel A. Gonzalez, Michael A. Gaglia, Gabriel Maluenda, Cedric Delhaye, Kohei Wakabayashi, Laurant Bonello, Axel De Labriolle, Loic Belle, Rebecca Torguson, Zhenyi Xue, Kimberly Kaneshige, Nelson Bernardo, Lowell F. Satler, Kenneth M. Kent, William O. Suddath, Augusto D. Pichard, Joseph Lindsay, Ron Waksman. (2010) Outcomes in Diabetic Versus Nondiabetic Patients Who Present With Acute Myocardial Infarction and Are Treated With Drug-Eluting Stents. The American Journal of Cardiology 105:6, 819-825
CrossRef42
Rainer Hoffmann, Giadino Nitendo, Verena Deserno, Umar Adamu, Mohammed Almalla, Rüdiger Blindt, Felix Vogt. (2010) Follow-up results after interventional treatment of infarct-related saphenous vein graft occlusion. Coronary Artery Disease 21:2, 61-64
CrossRef43
Gregg W. Stone, Stuart J. Pocock. (2010) Randomized Trials, Statistics, and Clinical Inference. Journal of the American College of Cardiology 55:5, 428-431
CrossRef44
Jon C. George, George D. Dangas. (2010) 2009 Focused Updates to Guidelines in ST-Elevation Myocardial Infarction and Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions 3:2, 256-258
CrossRef45
Rahul Sakhuja, Laura Mauri. (2010) Controversies in the Use of Drug-Eluting Stents for Acute Myocardial Infarction: A Critical Appraisal of the Data. Annual Review of Medicine 61:1, 215-231
CrossRef46
Marco T. Castagna, Mauricio Cavalieri Machado, Jordan Vieira de Oliveira. (2010) Left main intervention in myocardial infarction. Catheterization and Cardiovascular Interventions 75:2, 225-228
CrossRef47
Federico Piscione, Raffaele Piccolo, Salvatore Cassese, Gennaro Galasso, Roberta De Rosa, Claudia D’Andrea, Massimo Chiariello. (2010) Effect of drug-eluting stents in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a meta-analysis of randomised trials and an adjusted indirect comparison. EuroIntervention 5:7, 853-860
CrossRef48
Agustín Albarrán, Josepa Mauri, Eduardo Pinar, José Antonio Baz. (2010) Actualización en cardiología intervencionista. Revista Española de Cardiología 63, 86-100
CrossRef49
Edward L. Hannan, Zaza Samadashvili, Gary Walford, David R. Holmes, Alice K. Jacobs, Nicholas J. Stamato, Ferdinand J. Venditti, Samin Sharma, Spencer B. King. (2010) Culprit Vessel Percutaneous Coronary Intervention Versus Multivessel and Staged Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Patients With Multivessel Disease. JACC: Cardiovascular Interventions 3:1, 22-31
CrossRef50
(2010) Advances in surgery. ANZ Journal of Surgery 80:1-2, 107-109
CrossRef51
Sandhir B. Prasad, Walid Ahmar, Yuvaraj Malaiapan, Ian T. Meredith. (2010) Drug-eluting Stents for the Treatment of Acute Myocardial Infarction: The View to the HORIZONS. Heart, Lung and Circulation 19:1, 11-18
CrossRef52
Frederick G. Kushner, Mary Hand, Sidney C. Smith, Spencer B. King, Jeffrey L. Anderson, Elliott M. Antman, Steven R. Bailey, Eric R. Bates, James C. Blankenship, Donald E. Casey, Lee A. Green, Alice K. Jacobs, Judith S. Hochman, Harlan M. Krumholz, Douglass A. Morrison, Joseph P. Ornato, David L. Pearle, Eric D. Peterson, Michael A. Sloan, Patrick L. Whitlow, David O. Williams. (2009) 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update). Catheterization and Cardiovascular Interventions 74:7, E25-E68
CrossRef53
Gioel Gabrio Secco, Carlo Di Mario. (2009) Conference Scene: A congress report. Interventional Cardiology 1:2, 161-164
CrossRef54
Frederick G. Kushner, Mary Hand, Sidney C. Smith, Spencer B. King, Jeffrey L. Anderson, Elliott M. Antman, Steven R. Bailey, Eric R. Bates, James C. Blankenship, Donald E. Casey, Lee A. Green, Judith S. Hochman, Alice K. Jacobs, Harlan M. Krumholz, Douglass A. Morrison, Joseph P. Ornato, David L. Pearle, Eric D. Peterson, Michael A. Sloan, Patrick L. Whitlow, David O. Williams. (2009) 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update). Journal of the American College of Cardiology 54:23, 2205-2241
CrossRef55
Claudia Clavijo, Tobin Strom, Vanessa Moll, Ronald Betts, Yan Ling Zhang, Uwe Christians, Jamie Bendrick-Peart. (2009) Development and validation of a semi-automated assay for the highly sensitive quantification of Biolimus A9 in human whole blood using high-performance liquid chromatography–tandem mass spectrometry. Journal of Chromatography B 877:29, 3506-3514
CrossRef56
Amar Krishnaswamy, A. Michael Lincoff, Venu Menon. (2009) Magnitude and consequences of missing the acute infarct-related circumflex artery. American Heart Journal 158:5, 706-712
CrossRef57
RISHI SUKHIJA, WILBERT S. ARONOW, CHANDRASEKAR PALANISWAMY, TARUNJIT SINGH, CHUL AHN, KUMAR KALAPATAPU, BHAVNA CHATURVEDI, ANTHONY L. PUCILLO, CARMINE SORBERA, PRIYANKA KAKAR, MELVIN B. WEISS, VIMAL MEHTA, CRAIG E. MONSEN. (2009) Major Adverse Cardiac Events at Long-Term Follow-Up in Patients Treated With Single versus Multiple Stents during Single-Vessel Percutaneous Coronary Intervention. Journal of Interventional Cardiology 22:5, 427-430
CrossRef58
R. Corti, S. Toggweiler. (2009) PCI in acute left main disease: a paradigm shift or a new reality?. European Heart Journal 30:19, 2295-2296
CrossRef59
C. Jámbor, M. Spannagl, B. Zwissler. (2009) Perioperatives Management von Patienten mit Koronarstents bei nichtherzchirurgischen Eingriffen. Der Anaesthesist 58:10, 971-985
CrossRef60
Robert A. Byrne, Nikolaus Sarafoff, Adnan Kastrati, Albert Schömig. (2009) Drug-Eluting Stents in Percutaneous Coronary Intervention. Drug Safety 32:9, 749-770
CrossRef61
Gregor Leibundgut, Fabian Nietlispach, Undine Pittl, Hanspeter Brunner-La Rocca, Christoph A. Kaiser, Matthias E. Pfisterer. (2009) Stent thrombosis up to 3 years after stenting for ST-segment elevation myocardial infarction versus for stable angina—Comparison of the effects of drug-eluting versus bare-metal stents. American Heart Journal 158:2, 271-276
CrossRef62
A. V. Finn, G. Nakazawa, F. Kolodgie, R. Virmani. (2009) Drug eluting or bare metal stent for acute myocardial infarction: an issue of safety?. European Heart Journal 30:15, 1828-1830
CrossRef63
George W. Vetrovec. (2009) SES for AMI: Moving in the right direction. Catheterization and Cardiovascular Interventions 74:2, 333-334
CrossRef64
MANABU OGITA, TOMOHIRO NAKAMURA, NAOKI FUJIWARA, KENICHI SAKAKURA, HIROSHI FUNAYAMA, YOSHITAKA SUGAWARA, NORIFUMI KUBO, JUNYA AKO, SHINICHI MOMOMURA. (2009) Long-Term Clinical Follow-up after Sirolimus-Eluting Stent versus Bare Metal Stent Implantation in Patients with Acute Coronary Syndrome. Journal of Interventional Cardiology 22:3, 216-221
CrossRef65
Simon R. Dixon, Cindy L. Grines, William W. O'Neill. (2009) The Year in Interventional Cardiology. Journal of the American College of Cardiology 53:22, 2080-2097
CrossRef66
Henri Roukoz, Anthony A. Bavry, Michael L. Sarkees, Girish R. Mood, Dharam J. Kumbhani, Mark G. Rabbat, Deepak L. Bhatt. (2009) Comprehensive Meta-Analysis on Drug-Eluting Stents versus Bare-Metal Stents during Extended Follow-up. The American Journal of Medicine 122:6, 581.e1-581.e10
CrossRef67
Marco Roffi, Franz R. Eberli. (2009) Diabetes and acute coronary syndromes. Best Practice & Research Clinical Endocrinology & Metabolism 23:3, 305-316
CrossRef68
Stone, Gregg W., Lansky, Alexandra J., Pocock, Stuart J., Gersh, Bernard J., Dangas, George, Wong, S. Chiu, Witzenbichler, Bernhard, Guagliumi, Giulio, Peruga, Jan Z., Brodie, Bruce R., Dudek, Dariusz, Möckel, Martin, Ochala, Andrzej, Kellock, Alison, Parise, Helen, Mehran, Roxana, . (2009) Paclitaxel-Eluting Stents versus Bare-Metal Stents in Acute Myocardial Infarction. New England Journal of Medicine 360:19, 1946-1959
Full Text69
Dennis T. Ko, Maria Chiu, Helen Guo, Peter C. Austin, Ron Goeree, Eric Cohen, Marino Labinaz, Jack V. Tu. (2009) Safety and Effectiveness of Drug-Eluting and Bare-Metal Stents for Patients With Off- and On-Label Indications. Journal of the American College of Cardiology 53:19, 1773-1782
CrossRef70
John Lasala, David Cox, Stephen Lewis, Peter Tadros, Robert Haas, Marc Schweiger, Anil Chhabra, William Untereker, Ruth Starzyk, Stephen Mascioli, Keith Dawkins, Donald Baim. (2009) Expanded use of the TAXUS Express Stent: two-year safety insights from the 7,500 patient ARRIVE Registry programme. EuroIntervention 5:1, 67-77
CrossRef71
Somjot S. Brar, Martin B. Leon, Gregg W. Stone, Roxana Mehran, Jeffrey W. Moses, Simerjeet K. Brar, George Dangas. (2009) Use of Drug-Eluting Stents in Acute Myocardial Infarction. Journal of the American College of Cardiology 53:18, 1677-1689
CrossRef72
(2009) Drug-Eluting versus Bare-Metal Stents in Acute Myocardial Infarction. New England Journal of Medicine 360:3, 300-302
Full Text73
Keun-Ho Park, Myung Ho Jeong, Min Goo Lee, Jum Suk Ko, Shin Eun Lee, Won Yu Kang, Soo Hyun Kim, Doo Sun Sim, Nam Sik Yoon, Hyun Ju Youn, Young Joon Hong, Hyung Wook Park, Ju Han Kim, Youngkeun Ahn, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang. (2009) Efficacy of Triple Anti-Platelet Therapy Including Cilostazol in Acute Myocardial Infarction Patients Undergoing Drug-Eluting Stent Implantation. Korean Circulation Journal 39:5, 190
CrossRef74
Federico Piscione, Raffaele Piccolo, Salvatore Cassese, Gennaro Galasso, Massimo Chiariello. (2009) Clinical impact of sirolimus-eluting stent in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trials. Catheterization and Cardiovascular InterventionsNA-NA
CrossRef75
David Austin, Keith Oldroyd, Jill Pell. (2009) Observational studies of drug-eluting stents – some are more equal than others.. EuroIntervention 4:4, 419-423
CrossRef
- Letters
